Document:

<PAGE>

                                                                     EXHIBIT 4.3

                         REGISTRATION RIGHTS AGREEMENT
                         -----------------------------

     THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made as of March
14, 2001 (the "Effective Date"), by and between IVAX DIAGNOSTICS INC., formerly
known as B2BSTORES.COM INC., a Delaware corporation (the "Company"), and IVAX
CORPORATION, a Florida corporation ("IVAX").

                                    RECITALS

          WHEREAS, on November 21, 2000 IVAX, IVAX DIAGNOSTICS, INC.
("Diagnostics"), a Florida corporation and wholly-owned subsidiary of IVAX, and
the Company entered into a Merger Agreement whereby Diagnostics merged with and
into the Company;

          WHEREAS, pursuant to the Merger all of the issued and outstanding
shares of common stock, par value $.O1 per share of Diagnostics ("Diagnostics
Common Shares") were converted into IVAX' right to receive 20,000,000 shares of
Common Stock of the Company (the "Shares"); and

          WHEREAS, in order to induce IVAX to enter into the Merger and accept
the Shares as consideration for the Diagnostics' Common Stock, the Company and
IVAX agree that this Agreement shall govern the rights of IVAX to cause the
Company to Register the Shares.

                                   AGREEMENT

          NOW, THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

     Section 1. Definitions. For purposes of this Agreement:
                -----------

     In addition to terms defined elsewhere in this Agreement, capitalized terms
used herein shall have the meanings as defined below. Such terms shall be
applicable to both the singular and plural forms of any of the terms herein
defined.

          (a) "Act" means the Securities Act of 1933, as amended.

          (b) "Common Stock" means the common stock, par value $.001 per share,
of the Company.

          (c)"Exchange Act" means the Securities Exchange Act of 1934, as
amended.

          (d) "Form S-3" means such form under the Act as in effect on the date
hereof or any Registration form under the Act subsequently adopted by the SEC
that permits inclusion or incorporation of substantial information by reference
to other documents filed by the Company with the SEC.
<PAGE>

          (e) "Holder" means any person owning Registrable Securities as of the
Effective Date or any permitted assignee thereof.

          (f) "Register", "Registered," and "Registration" refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the Act, and the declaration or ordering of
effectiveness of such registration statement or document.

          (g) "Registrable Securities" means the Shares.

          (h) "SEC" means the Securities and Exchange Commission.

          Section 2. Company Registration. If at any time after the one year
                     --------------------
anniversary of the Effective Date the Company proposes to Register (including
for this purpose a Registration effected by the Company for shareholders other
than the Holders) any of its stock or other securities under the Act in
connection with the public offering of such securities solely for cash (other
than a Registration relating solely to the sale of securities to participants in
a Company stock plan or a Registration on any form that does not include
substantially the same information as would be required to be included in a
Registration statement covering the sale of the Registrable Securities), the
Company shall, at such time, promptly give each Holder written notice of such
Registration. Upon the written request of each Holder given within twenty (20)
days after mailing of such notice by the Company in accordance with Section
14(e), the Company shall, subject to the provisions of Section 8, include in the
Registration statement all of the Registrable Securities that each such Holder
has requested to be Registered.

     Section 3. Form of S-3 Registration. If at any time the Company shall
                ------------------------
receive from any Holder or Holders a written request or requests that the
Company effect a Registration on Form S-3 and any related qualification or
compliance with respect to all or a part of the Registrable Securities owned by
such Holder or Holders, the Company will:

          (a) Promptly give written notice of the proposed Registration, and any
related qualification or compliance, to all other Holders; and

          (b) As soon as practicable, use commercially reasonable efforts to
effect such Registration and all such qualifications and compliances as may be
so requested and as would permit or facilitate the sale and distribution of all
or such portion of such Holder's or Holders' Registrable Securities as are
specified in such request, together with all or such portion of the Registrable
Securities of any other Holder or Holders joining in such request as are
specified in a written request given to the Company within fifteen (15) days
after receipt of such written notice from the Company; provided, however, that
                                                       --------  -------
the Company shall not be obligated, pursuant to this Section 3, to effect any
such Registration, qualification or compliance (i) if Form S-3 is not available
for such offering by the Holders; (ii) if the Holders, together with the holders
of any other securities of the Company entitled to inclusion in such
Registration, propose to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public (net of any underwriters' discounts
or commissions) of less than S 1,000,000; (iii) if the Company shall furnish to
the Holders a certificate
<PAGE>

signed by the Chief Executive Officer (or, if there is no Chief Executive
Officer, by the President) of the Company stating that in the good faith
judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its shareholders for such Form S-3 Registration
to be effected at such time, in which event the Company shall have the right to
defer the filing of the Form S-3 Registration statement for a period of not more
than one hundred twenty (120) days after receipt of the request of the Holder or
Holders under this Section 3; provided, however, that the Company shall not
                              --------  -------
utilize this right more than once in any twelve (12) month period; (iv) if the
request is received at any time before the one year anniversary of the Effective
Date; (v) in any particular jurisdiction in which the Company would be required
to qualify to do business or to execute a general consent to service of process
in effecting such Registration, qualification or compliance; or (vi) if the
Company has already effected a total of two registrations on Form S-3 for the
Holders pursuant to this Section 3.

          (c) Subject to the foregoing, the Company shall file a Registration
statement covering the Registrable Securities to be Registered as soon as
practicable after receipt of the request or requests of the Holders.

     Section 4. Obligations of the Company. Whenever required under this
                --------------------------
Agreement to effect the Registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:

          (a) Prepare and file with the SEC a Registration statement with
respect to such Registrable Securities and use its commercially reasonable
efforts to cause such Registration statement to become effective, and, upon the
request of the Holders of a majority of the Registrable Securities Registered
thereunder, keep such Registration statement effective until the earlier to
occur of (i) all Registrable Securities are sold under such Registraion
statement; and (ii) the date on which all Registrable Securities may be sold
pursuant to Rule 144(k) of the Act.

          (b) Prepare and file with the SEC such amendments and supplements to
such Registration statement and the prospectus used in connection with such
Registration statement as may be necessary to comply with the provisions of the
Act with respect to the disposition of all securities covered by such
Registration statement.

          (c) Furnish to the Holders such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
Act, and such other documents as they may reasonably request in order to
facilitate the disposition thereunder of Registrable Securities owned by them.

          (d) Use its commercially reasonable efforts to Register and qualify
the securities covered by such Registration statement under such other
securities or blue sky laws of such jurisdictions as shall be reasonably
requested by the Holders; provided, however, that the Company shall not be
                          --------  -------
required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states
or jurisdictions.

                                      -3-
<PAGE>

          (e) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary
form, with the managing underwriter of such offering. Each Holder participating
in such underwriting shall also enter into and perform its obligations under
such an agreement.

          (f) Notify each Holder of Registrable Securities covered by such
Registration statement at any time when a prospectus relating thereto is
required to be delivered under the Act of the happening of any event as a result
of which the prospectus included in such Registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances then existing.

          (g) Use reasonable efforts to cause all such Registrable Securities
Registered pursuant hereunder to be listed on each securities exchange or
nationally recognized quotation system on which similar securities issued by the
Company are then listed, if any.

     Section 5. Furnish Information. It shall be a condition precedent to the
                -------------------
obligations of the Company to take any action pursuant to this Agreement with
respect to the Registrable Securities of any selling Holder that such Holder
shall fumish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the Registration of such Holder's Registrable
Securities and represent and warrant that any such information furnished does
not contain any untrue statement of a material fact or omit to state a material
fact required to be stated in the Registration Statement.

     Section 6. Expenses of Form S-3 Registration. All expenses other than
                ---------------------------------
underwriting discounts and commissions incurred in connection with
Registrations, filings or qualifications pursuant to Section 3, including,
without limitation, all Registration, filing and qualification fees, printers'
and accounting fees, and fees and disbursements of counsel for the Company shall
be borne by the Company, but excluding underwriting discounts and commissions
relating to the Registered Securities and fees and expenses of counsel for any
selling Holder; provided, however, that the Company shall not be required to pay
                --------  -------
for any expenses of any Registration proceeding begun pursuant to Section 3 if
the Registration request is subsequently withdrawn at the request of the Holders
of a majority of the Registrable Securities to be Registered (in which case all
participating Holders shall bear such expenses; provided further, however, that
                                                ----------------  -------
if at the time of such withdrawal, the Holders have learned of a material
adverse change in the condition, business, or prospects of the Company from that
known to the Holders at the time of their request and have withdrawn the request
with reasonable promptness following disclosure by the Company of such material
adverse change, then the Holders shall not be required to pay any of such
expenses and shall retain their rights pursuant to Section 3.

     Section 7. Expenses of Company Registration. The Company shall bear and pay
                --------------------------------
all expenses incurred in connection with any Registration, filing or
qualification of Registrable

                                      -4-
<PAGE>

Securities with respect to the Registrations pursuant to Section 2 for each
Holder, including, without limitation, all Registration, filing, and
qualification fees, printers' and accounting fees relating or apportionable
thereto and the fees and disbursements of counsel for the Company, but excluding
underwriting discounts and commissions relating to Registrable Securities and
fees and expenses of counsel for any selling Holder (if other than counsel to
the Company).

     Section 8. Underwriting Requirements. In connection with any offering
                -------------------------
involving an underwriting of shares of the Company's capital stock, the Company
shall not be required to include any of the Holders' securities in such
underwriting unless they accept the terms of the underwriting as agreed upon
between the Company and the underwriters selected by it (or by other persons
entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success
of the offering by the Company. If the total amount of securities, including
Registrable Securities, requested by shareholders to be included in such
offering exceeds the amount of securities sold other than by the Company that
the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities,
which the underwriters determine in their sole discretion will not jeopardize
the success of the offering. All securities to be sold by the Company shall be
included in the offering prior to the inclusion of any Registrable Shares. The
securities to be sold by shareholders shall be apportioned pro rata among the
selling shareholders according to the total amount of securities entitled to be
included therein owned by each selling shareholder or in such other proportions
as shall mutually be agreed to by such selling shareholders. For purposes of the
preceding sentence concerning apportionment, for any selling shareholder that is
a holder of Registrable Securities and that is a partnership or corporation, the
affiliated partnerships, the partners, retired partners and shareholders of such
holder, or the estates and family members of any such partner and retired
partners and any trusts for the benefit of any the foregoing persons shall be
deemed to be a single "selling shareholder," and any pro-rata reduction with
respect to such "selling shareholder" shall be based upon the aggregate amount
of shares carrying Registrations rights owned by all entities and individuals
included in such "selling shareholder," as defined in this sentence.

     Section 9. Indemnification.
                ---------------

          (a) To the extent permitted by law, the Company will indemnify and
hold harmless each Holder, any underwriter (as defined in the Act) for such
Holder and each person, if any, who controls such Holder or underwriter within
the meaning of the Act or the Exchange Act, against any losses, claims, damages,
or liabilities (joint or several) to which they may become subject under the
Act, the Exchange Act or other federal or state securities law, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise
out of or are based upon any of the following statements, omissions or
violations (collectively, a "Violation"): (i) any untrue statement or alleged
untrue statement of a material fact contained in such Registration statement,
including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading, or (iii) any violation or alleged

                                      -5-
<PAGE>

violation by the Company of the Act, the Exchange Act, any state securities law
or any rule or regulation promulgated under the Act, the Exchange Act or any
state securities law; and the Company will pay to each such Holder, underwriter
or controlling person, as incurred, any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss,
claim, damage, liability, or action; provided, however, that the indemnity
                                     --------  -------
agreement contained in this Section 9 shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such
settlement is effected without the consent of the Company (which consent shall
not be unreasonably withheld), nor shall the Company be liable in any such case
for any such loss, claim, damage, liability, or action to the extent that it
arises out of or is based upon a Violation that occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such Registration by any such Holder, underwriter or controlling person.

          (b) To the extent permitted by law, each selling Holder will indemnify
and hold harmless the Company, each of its directors, each of its officers who
has signed the Registration statement, each person, if any, who controls the
Company within the meaning of the Act, any underwriter, any other shareholder
selling securities in such Registration statement and any controlling person of
any such underwriter or other shareholder, against any losses, claims, damages,
or liabilities (joint or several) to which any of the foregoing persons may
become subject, under the Act, the Exchange Act or other federal or state
securities law, insofar as such losses, claims, damages, or liabilities (or
actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder expressly for use in connection with such Registration; and each such
Holder will pay, as incurred, any legal or other expenses reasonably incurred by
any person intended to be indemnified pursuant to this Section 9, in connection
with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this
        -----------------
Section 9 shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability or action if such settlement is effected without the consent
of the Holder, which consent shall not be unreasonably withheld; provided,
                                                                 --------
however, that, in no event shall any indemnity under this Section 9 exceed the
-------
net proceeds from the offering received by such Holder.

          (c) Promptly after receipt by an indemnified party under Section 9 of
notice of commencement of any action (including any governmental action), such
indemnified party will, if a claim in respect thereof is to be made against any
indemnifying party under this Section 9, delivery to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have
the right to participate in, and, to the extent the indemnifying party so
desires, jointly with any other indemnifying party similarly noticed, to assume
the defense thereof with counsel mutually satisfactory to the parties; provided,
                                                                       --------
however, that an indemnified party (together with all other indemnified parties
-------
that maybe represented without conflict by one counsel) shall have the right to
retain one separate counsel, with the reasonable fees and expenses to be paid by
the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver
written

                                      -6-
<PAGE>

notice to the indemnifying party within a reasonable time of the commencement of
any such action, if materially prejudicial to its ability to defend such action,
shall relieve such indemnifying party of any liability to be indemnified party
under this Section 9, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 9.

          (d) The obligations of the Company and Holders under this Section 9
shall survive the completion of any offering of Registrable Securities in a
Registration statement under this Agreement.

     Section 10. Reports Under the Exchange Act. With a view to making available
                 ------------------------------
to the Holders the benefits of Rule 144 promulgated under the Act and any other
rule or regulation of the SEC that may at any time permit a Holder to sell
securities of the Company to the public without Registration or pursuant to a
Registration on Form S-3, the Company agrees to:

          (a) Make and keep public information available, as those terms are
understood and defined in SEC Rule 144, at all times after the effective date of
the first Registration statement filed by the Company for the offering of its
securities to the general public;

          (b) Take such action, including the voluntary Registration of its
Common Stock under Section 12 of the Exchange Act, as is necessary to enable the
Holders to utilize Form S-3 for the sale of their Registrable Securities, such
action to be taken as soon as practicable after the end of the fiscal year in
which the first Registration statement filed by the Company for the offering of
its securities to the general public is declared effective;

          (c) File with the SEC in a timely manner all reports and other
documents required of the Company under the Act and the Exchange Act; and

          (d) Furnish to any Holder, so long as the Holder owns any Registrable
Securities, forthwith upon request (i) a written statement by the Company that
it has complied with the reporting requirements of SEC Rule 144 (at any time
after ninety (90) days after the effective date of the first Registration
statement filed by the Company), the Act and the Exchange Act (at any time after
it has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time
after it so qualifies), (ii) a copy of the most recent annual or quarterly
report of the Company and such other reports and documents so filed by the
Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the
selling of any such securities without Registration or pursuant to such form.

     Section 11. Assignment of Registration Rights. The rights to cause the
                 ---------------------------------
Company to Register Registrable Securities pursuant to this Agreement may be
assigned (but only with all related obligations) by a Holder to a transferee or
assignee of such securities.

                                      -7-
<PAGE>

     Section 12. "Market Stand-Off" Agreement. IVAX hereby agrees that, during
                  ---------------------------
the period of duration (not to exceed one hundred eighty (180) days) specified
by the Company and an underwriter of common stock or other securities of the
Company, following the effective date ofthe Registration statement for a public
offering of the Company's securities filed under the Act, it shall not, to the
extent requested by the Company and such underwriter, directly or indirectly
sell, offer to sell, contract to sell (including, without limitation, any short
sale), grant any option to purchase or otherwise transfer or dispose of (other
than to donees who agree to be similarly bound) any securities of the Company
held by it at any time during such period, except common stock included in such
Registration; provided, however, that all executive officers, directors and, in
              --------  -------
the case of the Company's initial public offering, greater than five percent
(5%) stockholders of the Company enter into similar agreements. In order to
enforce the foregoing covenant, the Company may impose stoptransfer instructions
with respect to the securities of each Holder until the end of such period.

     Section 13. Termination of Registration Rights. No Holder shall be entitled
                 ----------------------------------
to exercise any right provided for in this Agreement after the earlier of (i)
five (5) years after the Effective Date, or (ii) such time at which all
Registrable Securities held by such Holder can be sold in any threemonth period
without Registration in compliance with Rule 144 of the Act.

     Section 14. Miscellaneous.
                 -------------

          (a) Successors and Assigns. Except as otherwise provided herein, the
              ----------------------
terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the respective successors and assigns of the parties (including
transferees of any shares of Registrable Securities). Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement.

          (b) Governing Law. This Agreement shall be governed by and construed
              -------------
under the laws of the State of Delaware, without giving effect to any choice of
law or conflict of law provision or rule (whether of the State of Delaware or
any other jurisdiction) that would cause the applications of the laws of any
jurisdiction other than the State of Delaware.

          (c) Counterparts. This Agreement may be executed in two or more
              ------------
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          (d) Titles and Subtitles. The titles and subtitles used in this
              --------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

          (e) Notices. Unless otherwise provided, any notice required or
              -------
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or upon
delivery by confirmed facsimile transmission or nationally recognized overnight
courier services or three days following deposit with the United States Post

                                      -8-
<PAGE>

Office, by registered air mail (for international mail) or certified mail (for
domestic mail), postage prepaid and addressed to the party to be notified at the
address indicated for such party on the signature page hereof, or at such other
address as such party may designate by ten (10) days' advance written notice to
the other parties.

          (f) Expenses. If any action at law or in equity is necessary to
              --------
enforce or interpret the terms of this Agreement, the prevailing party shall be
entitled to reasonable attorneys' fees, costs and necessary disbursements in
addition to any other relief to which such party may be entitled.

          (g) Amendments and Waivers. Any term of this Agreement may be amended
              ----------------------
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only
with the written consent of the Company and the holders of at least a majority
of the Registrable Securities then outstanding.

          (h) Severability. If one or more provisions of this Agreement are held
              ------------
to be unenforceable under applicable law, such provision shall be excluded from
this Agreement, and the balance of the Agreement shall be interpreted as if such
provision were so excluded, and shall be enforceable in accordance with its
terms.

                 REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK

                                      -9-
<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written.

                                    COMPANY:

                                    IVAX DIAGNOSTICS, INC., F/K/A B2BSTORES.COM,
                                    INC.

                                    By:/s/ Giorgio D'urso
                                       -------------------------------
                                       Name: Giorgio D'urso
                                       Title: President & CEO
                                       Address: 2140 North Miami Avenue
                                                Miami, Florida 33137
                                       Facsimile: (305) 324-2385

                                    IVAX:

                                    IVAX CORPORATION

                                    By:/s/ Carol J. Gillespie
                                       -------------------------------
                                       Name: Carol J. Gillespie
                                       Title: Senior Vice President
                                       Address: 4400 Biscayne Boulevard
                                                Miami, Florida 33137
                                       Facsimile:(305) 575-6049

                 SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

                                       -10-<PAGE>

                                                                    EXHIBIT 10.2

         AGREEMENT BETWEEN IVAX DIAGNOSTICS, INC. AND SIGMA DIAGNOSTICS

     This Distributorship Agreement (hereinafter the "Agreement") is between
IVAX DIAGNOSTICS, Inc., a corporation existing under the laws of Florida,
(together with its affiliates Delta Biologicals, Diamedix Corporation, and
Immunovision, Inc., hereinafter referred to as "IVAX Diagnostics"),and SIGMA
DIAGNOSTICS, Inc. (hereinafter "SIGMA"), a corporation existing under the laws
of Missouri.

     WHEREAS, IVAX DIAGNOSTICS desires to sell and/or market its products and
SIGMA desires to purchase certain of IVAX DIAGNOSTICS's products for resale to
customers; and

     WHEREAS, the parties desire to enter into an agreement setting forth the
terms of their relationship;

     NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the parties do hereby agree as follows:

1.   Products. The product(s) of IVAX DIAGNOSTICS covered by this Agreement are
     set forth on Exhibit A attached hereto (hereinafter the "Product(s)"). For
     avoidance of doubt, "Product" or "Products" means only products purchased
     from IVAX DIAGNOSTICS, and marketed under a trademark or trade name of
     SIGMA. IVAX DIAGNOSTICS reserves the right to discontinue or modify the
     Products from time to time, and shall, to the extent practicable, give
     SIGMA at least six (6) months prior written notice before discontinuation
     or making changes to Product that would have an impact on any of IVAX
     DIAGNOSTICS product verifications or validations, or changes in raw
     materials that would alter the operating principle of the Products or other
     changes that could impact product labeling or promotional literature;
     provided, however, that IVAX DIAGNOSTICS shall be required to provide SIGMA
     with only reasonable advance notice where such discontinuance or
     modification is required to comply with any applicable legal or regulatory
     requirement or the unanticipated modification or unavailability of raw
     material. Additional products may be added to Exhibit A by mutual consent
     of the Parties.

2.   Appointment and Acceptance.

     (a)  IVAX DIAGNOSTICS hereby appoints SIGMA as their distributor of the
          Product(s) and grants SIGMA the right and license to import, use,
          possess, market, sell and distribute the Product(s) in the United
          States and outside the United States (the "Territory") and the right
          to extend to Affiliates, sub-distributors and purchasers rights of the
          same scope as granted herein

                                       1
<PAGE>

          to use, possess, market, sell and distribute Product(s) in the
          Territory subject to the provisions of Section 19 hereof.

     (b)  IVAX DIAGNOSTICS reserves the unlimited right to sell directly and
          through distributors products similar to the Product, under its own
          trademark or trade name or any other trade name or label.

          IVAX DIAGNOSTICS reserves the unlimited right to sell a product
          similar to the Product to any other company (ies), under any trade.

3.   Term and Renewal. The term of this Agreement shall be for a period of three
     (3) years, becoming effective on October 1, 2000 (the "Initial Term"), and
     shall automatically renew for additional and successive terms of one (1)
     year unless either party provides written notice of non-renewal at least
     ninety (90) days prior to the close of the Initial Term or of any
     anniversary date thereafter.

4.   Terms of Sale.

     (a)  The price for the Products is outlined in Exhibit A.

          The parties acknowledge that, in certain situations, SIGMA will face
          substantial competition in marketing the Products. In these highly
          competitive situations, IVAX DIAGNOSTICS will discuss with SIGMA the
          possibility of reducing the Purchase Price so that SIGMA is able to
          resell the Products at competitive prices.

     (b)  Payment terms are net forty-five (45) days from date of invoice.

     (c)  Title and risk of loss shall pass to SIGMA upon release of Products
          for shipment by IVAX DIAGNOSTICS to the designated carrier. All
          freight, applicable insurance charges, taxes, duties and similar
          charges shall be the responsibility of SIGMA. IVAX DIAGNOSTICS will be
          responsible for contracting freight services, in accordance with
          Section 8(a) of this Agreement, for which SIGMA will be billed on a
          shipment by shipment basis. Products are subject to acceptance by
          SIGMA upon receipt in accordance with Section 9.

5.   Reciprocal Termination Rights. Either IVAX DIAGNOSTICS or SIGMA may
     terminate this Agreement for cause immediately by written notice upon the
     occurrence of any of the following events:

                                       2
<PAGE>

     (a)  If the other ceases to do business or otherwise terminates its
          business operations;

     (b)  If the other shall fail to promptly secure or renew any license,
          registration, permit, authorization or approval necessary for the
          conduct of its business in the manner contemplated by this Agreement
          including an assessment of such systems and procedures as may be
          necessary for legal marketing within a country or territory or if any
          such license, registration, permit, authorization or approval is
          revoked or suspended and not reinstated within thirty (30) days;

     (c)  If the other breaches any material provision of this Agreement and
          fails to cure such breach within sixty (60) days of written notice
          describing the breach;

     (d)  If the other becomes insolvent or seeks protection under any
          bankruptcy, receivership, trust deed, creditors arrangement,
          composition or comparable proceeding, or if any such proceeding is
          instituted against the other (and not dismissed with sixty (60) days);
          or

     (e)  If a material representation of the other becomes false or misleading
          and the other party fails to render such representation true in all
          material respects within sixty (60) days of written notice describing
          the false or misleading representation.

6.   Rights Upon Termination. Any termination or expiration of the Agreement
     shall not release IVAX DIAGNOSTICS or SIGMA from paying any amount that may
     then be owed from any obligation at the date of termination hereunder. Each
     party understands that the rights of termination hereunder are absolute.
     Neither party shall incur any liability whatsoever for any damage, loss or
     expenses of any kind suffered or incurred by the other (or for any
     compensation to the other) arising from or incident to any termination of
     this Agreement in accordance with the terms hereof whether or not such
     party is aware of any such damage, loss or expenses. Termination is not the
     sole remedy under this Agreement and, whether or not termination is
     effected; all other remedies will remain available. IVAX DIAGNOSTICS agrees
     that during the period between the notice of termination and the effective
     date thereof, it will honor SIGMA's orders for Products.

7.   SIGMA's Duties. SIGMA shall:

     (a)  use reasonable commercial efforts to advertise and promote the sale of
          the Products in a commercially

                                       3
<PAGE>

          ethical manner, instructing its sales people to refrain from
          disparaging remarks about the competitive products of IVAX DIAGNOSTICS

     (b)  obtain advance written authorization from IVAX DIAGNOSTICS prior to
          returning any of the Products.

     (c)  maintain properly trained sales force of adequate size to represent
          and promote the sales of the Products and provide instructions to
          customers in the use of the Products. SIGMA shall be responsible for
          developing its own marketing plan and system for distributing the
          Products.

     (d)  carry in stock an inventory of Products sufficient to meet the needs
          of SIGMA's customers in the Territory.

     (e)  apply for and obtain all necessary licenses, permits and other
          authorizations required by local law or regulation in relation to the
          promotion, marketing, distribution and supply of the Products in any
          jurisdiction in which SIGMA sells the Products.

     (f)  maintain separate and detailed accurate and complete records of all
          transactions in respect of the Products, including, but not limited
          to, such records as identify all customer purchases by Product and
          serial and/or lot number, and possess the capability to notify all
          purchasers in the event of a Product recall or corrective action.

     (g)  make no contracts or commitments on behalf of IVAX DIAGNOSTICS or make
          any promises or representations or give any warranties or guarantees
          with respect to the Products on behalf of IVAX DIAGNOSTICS.

     (h)  comply with all laws and regulations and requirements applicable to a
          seller of in-vitro diagnostics products, and with all laws and
          regulations and requirements of governmental agencies having
          jurisdiction within the Territory.

8.   IVAX DIAGNOSTICS Duties. IVAX DIAGNOSTICS shall:

     (a)  make reasonable efforts, in good faith, to ship SIGMA's orders for
          Products within ninety (90) days from date of order receipt, at the
          prices set forth in Section 4(a). SIGMA shall specify the method of
          shipment and insurance and IVAX DIAGNOSTICS shall make reasonable
          efforts, in good faith, to comply with such specifications. If no such
          specification is made, or if the specification cannot be reasonably
          complied with

                                       4
<PAGE>

          after notice to SIGMA and an opportunity to resolve the issues
          surrounding IVAX DIAGNOSTICS alleged inability to comply, IVAX
          DIAGNOSTICS may select a reasonable manner of shipment and insurance.

     (b)  comply with all laws and regulations and requirements applicable to
          IVAX DIAGNOSTICS as a manufacturer of in-vitro diagnostic products,
          and assisting Sigma Diagnostics with meeting mutual requirements for
          documentation, quality and test data.

     (c)  except as authorized in writing by SIGMA; refrain absolutely from
          using the trademark or trade name and logo of SIGMA in connection with
          the marketing, distribution and sale of any Product.

     (d)  provide reasonable technical assistance to SIGMA's personnel necessary
          for the marketing of the Products.

     (e)  provide necessary documentation to assist SIGMA in meeting
          requirements to register Products in the Territory and comply with all
          laws and regulations, and requirements applicable to SIGMA as a
          distributor of in-vitro diagnostics products, and where possible,
          allow SIGMA to reference prior registrations by IVAX DIAGNOSTICS and
          if necessary to support CE marking, provide access to Sigma personnel
          as well as to notified body personnel of the IVAX manufacturing site
          as required by EU regulation.

     (f)  provide SIGMA with copies of the 510(k) premarket notifications
          submitted for the Products, if applicable, copies of documents
          describing specifications for the Products, and copies of all current
          and future correspondence with the FDA pertaining to the Products.
          IVAX DIAGNOSTICS will comply with the FDA's current GMP regulations in
          the manufacture of all Products. If needed to comply with any change
          in the law or FDA's GMP regulations or policies, Sigma shall be given
          the right to inspect IVAX DIAGNOSTICS manufacturing facilities for the
          Products and GMP records pertaining to the manufacture of the
          Products. If any action should be taken by the FDA to restrict or
          prevent the distribution of any of the Product for more than sixty
          (60) days, and such restriction is not due to any act or omission of
          SIGMA, then upon notice to IVAX DIAGNOSTICS, SIGMA shall have the
          right to terminate this Agreement as to such Product. In such event,
          IVAX DIAGNOSTICS shall replace any affected inventory of Products
          under this section or refund to SIGMA the purchase price it paid to
          IVAX DIAGNOSTICS for such inventory if IVAX DIAGNOSTICS is

                                       5
<PAGE>

          unable to replace the Products with comparable inventory. In addition,
          IVAX DIAGNOSTICS shall replace or repurchase any affected inventory of
          Product, which SIGMA replaces or repurchases from SIGMA's customers,
          at the price SIGMA paid IVAX DIAGNOSTICS for such inventory.

     (g)  comply with the Federal Food, Drug, and Cosmetic Act. The Products
          comprising each shipment or other delivery hereafter made by IVAX
          DIAGNOSTICS to, or on the order of, SIGMA, as of the date of such
          shipment or delivery, shall be, on such date, not adulterated or
          misbranded within the meaning of the Federal Food, Drug, and Cosmetic
          Act.

     (h)  perform any necessary task to insure the Product complies with any
          changes or redefinition's of standardization required by domestic and
          international scientific bodies covering minimum performance
          guidelines, which are economically feasible; provided that IVAX
          DIAGNOSTICS shall be entitled to adjust the purchase price of any
          Product affected by any such change to the extent of IVAX DIAGNOSTICS
          actual cost. If IVAX DIAGNOSTICS determines that the required change
          is not economically feasible, SIGMA shall have the right to pay the
          cost of such change and IVAX DIAGNOSTICS agrees to make such changes
          exclusively for Sigma.

     (i)  offer its products, which are competitive to the Products in a
          commercially ethical manner, instructing its sales people (i) not to
          disclose to customers that IVAX DIAGNOSTICS manufactures the Products
          for SIGMA and (ii) to refrain from disparaging remarks about the
          Products.

     (i)  during the term of this Agreement use its best efforts to modify the
          Product as required to maintain the Product's competitiveness in the
          market place as SIGMA and IVAX DIAGNOSTICS shall mutually agree upon
          in good faith. If such modifications are to be made to the Products
          purchased by SIGMA only, and are not used to modify the products that
          are sold by IVAX DIAGNOSTICS, then SIGMA shall be responsible for the
          cost associated with such modifications.

9.   Performance Standards.

     (a)  Quality specifications and Characteristics. IVAX DIAGNOSTICS shall
          deliver to SIGMA Products having the quality specifications agreed
          upon by the parties as set forth in the Product insert ("Quality

                                       6
<PAGE>

          Specifications"). These Quality Specifications and Characteristics may
          be modified from time to time to meet the future requirements of the
          parties and changes will be communicable to Sigma prior to
          implementation. In such cases, the parties agree to negotiate in good
          faith to find a solution that can be mutually agreed to by the
          parties.

     (b)  Certificates of Analysis. Concurrent with shipment, IVAX DIAGNOSTICS
          shall fax to SIGMA Certificates of Analysis, in the form set forth in
          Exhibit B, for each Product sold to SIGMA, confirming that the Product
          meets the Quality Specifications.

     (c)  Product Acceptance. SIGMA shall accept the Products based on the
          Certificate of Analysis delivered by IVAX DIAGNOSTICS. Should at
          anytime prior to expiration of the product dating the Product fails to
          meet the Quality Specifications, after toubleshooting, by Sigma
          personnel, the product does not meet the specifications SIGMA shall
          notify IVAX DIAGNOSTICS hereof and immediately thereafter provide IVAX
          DIAGNOSTICS with records and information pertaining to the problems
          associated with the Product. IVAX DIAGNOSTICS shall have 20days after
          receipt of SIGMA's notice within which t0 accept or reject SIGMA's
          claims. If, following a review of the problems and after conducting
          its own tests, IVAX DIAGNOSTICS agrees that such Product does not
          conform to the Quality Specifications, IVAX DIAGNOSTICS shall provide
          SIGMA, free of any additional charge, with new deliveries of the same
          quantity of the Products affected or items necessary to make the
          Product acceptable to Sigma, or, in IVAX DIAGNOSTICS discretion and at
          its cost, IVAX DIAGNOSTICS may promptly reprocess the nonconforming
          Products to meet the Quality Specifications. In either event, SIGMA
          shall return, at IVAX DIAGNOSTIC's expense, the particular lot or
          shipment of the Product, which does not comply with the Quality
          Specifications if requested to do so by IVAX DIAGNOSTICS. Any dispute
          arising under this Section 9(c) shall be resolved by arbitration as
          outlined in Section 21.

10.  Product Recall

     (a)  IVAX DIAGNOSTICS shall maintain an appropriate record of all claims
          made or to be made regarding the Products performance.

     (b)  Each party shall keep the other informed of any formal action relating
          to any specific lot of Product sold to SIGMA hereunder by any
          regulatory agency of any state,

                                       7
<PAGE>

          national government, or government agency having jurisdiction.

     (c)  Should any governmental or corporate action require a medical device
          reportable (MDR) event, a medical device vigilance system report
          (MDVS), a recall or field corrections, or withholding from market of
          Product sold by IVAX DIAGNOSTICS to SIGMA, SIGMA shall bear the
          reasonable, direct costs and expenses of the MDR, MDVS, recall or
          field correction if such action is the result of any fault or omission
          attributable to SIGMA. IVAX DIAGNOSTICS shall bear the reasonable,
          direct costs and expenses of the MDR, MDVS, recall or field correction
          and the actual costs of replacing the Products if such action is the
          result of any fault or omission attributable to IVAX DIAGNOSTICS.
          Should such MDR, MDVS, recall or field correction result from the
          fault of both parties, the parties shall share the costs of Products
          and the actual cost of replacing the Products in proportion to their
          respective degree of fault.

11.  Product Complaints

     (a)  Should either party experience any quality problem of any specific
          lot(s) of Product supplied to SIGMA by IVAX DIAGNOSTICS, such party
          will notify the other in writing by facsimile prior to the initiation
          of a MDR, MDVS, field correction or recall and the parties shall
          consult with each other regarding the proper corrective action,
          provided that each party retains the right to correct quality
          problems, as it deems appropriate, with or without the concurrence of
          the other. All information about Product complaints shall be
          considered "Confidential Information" under the terms of this
          Agreement.

     (b)  Either party shall immediately notify the other party in writing
          should it become aware of any defect or condition that renders any
          lot(s) of Product supplied by IVAX DIAGNOSTICS to SIGMA in violation
          of the United States Food, Drug and Cosmetic Act, or of a similar law
          of any jurisdiction or country where the Product is sold. The parties
          shall share with each other all data on confirmed lot specific Product
          complaints including, but not limited to, complaints or information
          regarding performance and/or allegations or reports of any negative
          effect from the use or misuse of such affected lot of Products as soon
          as such data is available. Each party will provide reasonable
          assistance to the other in resolving customer complaints to the extent
          the complaint arises out of any fault or omission of the party whose
          assistance is requested. However,

                                       8
<PAGE>

          SIGMA shall have sole responsibility and authority to interact
          directly with SIGMA's customers in the resolution of such complaints
          and IVAX DIAGNOSTICS agrees that it will only interact with SIGMA in
          such matters.

     (c)  IVAX DIAGNOSTICS shall evaluate and investigate all customer
          complaints in connection with the Products which may be brought to its
          attention, in writing, by SIGMA; which are believed in good faith by
          SIGMA to arise out of a fault or omission attributable to IVAX
          DIAGNOSTICS. Within twenty (20) calendar days following receipt from
          SIGMA of the original notification of each such complaint, IVAX
          DIAGNOSTICS agrees to provide SIGMA with a written interim or final
          complaint investigation report as well as corrective and preventive
          actions if applicable. All such Product complaints reported to IVAX
          DIAGNOSTICS by SIGMA shall be reviewed monthly by IVAX DIAGNOSTICS
          until closure, and a summary report thereof will be provided by IVAX
          DIAGNOSTICS to SIGMA.

     (d)  IVAX DIAGNOSTICS will report to SIGMA all data and/or information
          pertaining to adverse reports on any lot of Product supplied by IVAX
          DIAGNOSTICS for distribution by SIGMA, which would have a materially
          adverse impact on performance of the Products.

12.  Warranties.

     (a)  IVAX DIAGNOSTICS warrants that the Products which may be the subject
          of 510(k) premarket notifications have not been significantly changed
          or modified in design, components, method of manufacture or intended
          use from the Products as described in those 510 (k) premarket
          notifications, as applicable and will notify Sigma in advance of any
          changes in accordance with Section 1.

     (b)  IVAX DIAGNOSTICS warrants that all Products manufactured and supplied
          under this Agreement shall at the time of shipment meet the Quality
          Specifications of IVAX DIAGNOSTICS. IVAX DIAGNOSTICS further warrants
          that prior to shipment to SIGMA, all of its standard tests and quality
          control procedures have been carried out in relation to each lot of
          the Products with satisfactory results. IVAX DIAGNOSTICS MAKES NO
          WARRANTY EXPRESSED OR IMPLIED WITH RESPECT TO THE PRODUCTS BEYOND THAT
          WHICH IS SET FORTH IN THIS AGREEMENT INCLUDING THE WARRANTIES OF
          MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE.

     (c)  Upon its verification of any claim of defect or

                                       9
<PAGE>

          nonconformity of any Product arising out of a fault or omission
          attributable to IVAX DIAGNOSTICS, during the term of this Agreement,
          IVAX DIAGNOSTICS will provide SIGMA with a replacement to the extent
          necessary to honor IVAX DIAGNOSTICCs warranties contained in Section
          9(a) hereof, or make good any shortages or noncompleted deliveries and
          shall pay all associated freight and insurance associated therewith.

     (d)  IVAX DIAGNOSTICS liability under any legal or equitable theory to
          SIGMA with respect to the Products and/or the relationship described
          in this Agreement shall be limited to the replacement of the unit, or
          if impractical, return of the purchase price paid by SIGMA for such
          unit.

     (e)  As of the date hereof, IVAX DIAGNOSTICS warrants that it has no
          knowledge that the manufacture, use or sale of all or any of the
          Products under this Agreement, nor any method of using such Products
          infringes on any patent or other intellectual property right of a
          third party, and IVAX DIAGNOSTICS has not received any. notification
          from any third party alleging that the manufacture, use or sale of any
          such Product does or would infringe any patent or other intellectual
          property.

13.  Packaging and Intellectual Property. IVAX DIAGNOSTICS shall be responsible
     for packaging and labeling the Products. After the initial order SIGMA will
     distribute the Products only with all appropriate labeling, packaging, and
     Product literature and only under SIGMA's applicable trademarks and trade
     names and not with IVAX DIAGNOSTIC's trademarks or trade names. SIGMA
     recognizes IVAX DIAGNOSTICS right, title and interest in its patents,
     trademarks, trade names and copyrights, trade secrets and proprietary
     information in connection with the Products, and SIGMA shall not claim any
     ownership right thereto inconsistent with this Agreement, or dispute the
     validity thereof. In the event any third party shall contest IVAX
     DIAGNOSTICS rights to its patents, trademarks, trade names or copyrights,
     trade secrets or propriety rights, SIGMA shall, at IVAX DIAGNOSTICS sole
     expense, render reasonable assistance to IVAX DIAGNOSTICS in defending such
     claims. In the event that any third party shall contest the validity of any
     trademark or trade name of SIGMA used on or in relation to a Product, SIGMA
     will, at its own expense, defend and indemnify IVAX DIAGNOSTICS against any
     claim brought by such third party and will reimburse IVAX DIAGNOSTICS for
     all reasonable expenses incident to the adoption and implementation of a
     new SIGMA trademark or trade name for the Products.

                                       10
<PAGE>

14.  Compliance With Other Agreements. Each party represents and warrants that
     the execution and delivery by it of this Agreement and the performance by
     it of its obligations hereunder will not, with or without the giving of
     notice or the passage of time, violate any judgement, writ, injunction or
     order of any court, arbitration or governmental agency or conflict with,
     result in the breach of any provisions of, or the termination of, or
     constitute a default under, any agreement to which IVAX DIAGNOSTICS or
     SIGMA is a party or by which it is or may be bound.

15.  Indemnity.

     (a)  Except as limited by the remainder of this paragraph, IVAX DIAGNOSTICS
          hereby agrees to indemnify SIGMA against claims of third parties for
          injuries to their persons arising from the use of Products supplied by
          IVAX DIAGNOSTICS to SIGMA hereunder. This indemnity shall not apply
          to, and IVAX DIAGNOSTICS shall not be liable for, claims for injuries
          caused by or arising from:

          (1)  any act or failure to act on the part of SIGMA, its employees,
               representatives, agents, subdistributors or affiliates in
               packaging, handling, storing, promoting or otherwise distributing
               such Products; or

          (2)  any representation or warranty concerning the Products made by or
               on behalf of SIGMA and not specifically authorized by IVAX
               DIAGNOSTICS; or

          (3)  claims where the use of the Products by any customer was not in
               accordance with the use prescribed by IVAX DIAGNOSTICS; or

          (4)  SIGMA's failure to disseminate to purchasers or end-users any
               Product Information which IVAX DIAGNOSTICS has made available to
               SIGMA; or

          (5)  claims where IVAX DIAGNOSTICS has not been notified in writing
               within thirty (30) days of SIGMA's first notice of the claim; or

          (6)  claims where SIGMA fails to furnish evidence in its possession or
               fails to fully cooperate with IVAX DIAGNOSTICS in preparing the
               defense;

          (7)  claims where IVAX DIAGNOSTICS is not given the option to assume
               the sole defense of the claim at IVAX DIAGNOSTIC's expense.

                                       11
<PAGE>

     (b)  Except as limited by the remainder of this paragraph, SIGMA hereby
          agrees to indemnify IVAX DIAGNOSTICS against claims of third parties
          arising from the use of Products supplied by IVAX DIAGNOSTICS to SIGMA
          hereunder. This indemnity shall not apply to, and SIGMA shall not be
          liable for, claims caused by or arising from:

          (1)  any act or failure to act on the part of IVAX DIAGNOSTICS, its
               employees, representatives, agents or affiliates in
               manufacturing, testing, packaging, labeling, handling or storing
               such Products; or

          (2)  the breach of any representation or warranty concerning the
               Products made by or on behalf of IVAX DIAGNOSTICS; or

          (3)  claims where SIGMA has not been notified in writing within thirty
               (30) days of IVAX DIAGNOSTICS' first notice of the claim; or

          (4)  claims where IVAX DIAGNOSTICS fails to furnish evidence in its
               possession or fails to fully cooperate with SIGMA in preparing
               the defense; or

          (5)  claims where SIGMA is not given the option to assume the sole
               defense of the claim at SIGMA's expense.

     (c)  IVAX DIAGNOSTICS shall indemnify SIGMA from any claims of patent
          infringement relating to a Product subject to this Agreement provided
          SIGMA gives IVAX DIAGNOSTICS notice within thirty (30) days of SIGMA'
          s first notice of the claim, and permits IVAX DIAGNOSTICS to assume
          the sole defense of the claim at IVAX DIAGNOSTICS expense; provided,
          however, that the claim is not based on (i) the sale or use of any
          Product in combination with any other product which is not
          specifically authorized by IVAX DIAGNOSTICS; (ii) the application of
          any Product in any manner not specifically authorized by IVAX
          DIAGNOSTICS.

     (d)  SIGMA shall indemnify IVAX DIAGNOSTICS from any claims of trademark
          infringement relating to a Product subject to this Agreement, provided
          IVAX DIAGNOSTICS gives SIGMA notice within thirty (30) days of IVAX
          DIAGNOSTICS' first notice of the claim, and permits SIGMA to assume
          the sole defense of the claim at SIGMA'S expense; and provided that
          the claim is based on the use of a SIGMA trademark or trade name.

                                       12
<PAGE>

     (e)  Not withstanding anything above to the contrary, in the event of a 3rd
          party claim arising out of this Agreement, in which neither IVAX
          DIAGNOSTICS or SIGMA is in breach of this Agreement or is negligent,
          each party shall pay its respective legal expenses and damages caused
          by such claim.

16.  Force Majeure. Neither party shall be responsible for any failure to
     perform due to causes beyond its control. These causes shall include, but
     not be limited to, fire, storm, flood, earthquake, explosion, wars, riots,
     civil disorder, sabotage, quarantine restrictions, labor disputes, labor
     shortages, transportation embargoes, or failure or delays or disruption in
     manufacturing process, curtailment of or failure in obtaining fuel or
     electrical power, or the acts of any governmental authority, or
     instrumentality's, orders of any court or tribunal whether foreign or
     domestic, exchange restrictions, acts of God, acts of the Federal
     Government or any agency thereof, acts of any state or local government or
     agency thereof, or shortage of materials or any similar or dissimilar
     occurrence beyond the reasonable control of the party which is prevented,
     interrupted or delayed in the performance of its obligations hereunder. In
     no event shall IVAX DIAGNOSTICS be under any obligations to purchase
     Products or similar products from any third party in order to supply same
     to SIGMA hereunder. Any force majeure event shall not excuse performance by
     the party but shall delay performance, unless such force majeure continues
     for a period in excess of one hundred thirty five(135) days. In such event,
     the party seeking performance, as its sole and exclusive remedy, many
     cancel its obligations under this Agreement.

17.  Insurance. IVAX DIAGNOSTICS and SIGMA shall keep in force during the term
     of this Agreement product liability insurance, in such amounts as may be
     customary for like sized businesses undertaking like responsibilities to
     those contemplated by this Agreement. SIGMA and IVAX DIAGNOSTICS shall
     submit a certificate of insurance to the other evidencing such coverage
     upon written request therefor.

18.  Confidentiality.

     (a)  Confidentiality Defined. For the purposes of this Agreement, the term
          "Confidential Information" shall be any information relating to the
          Products, including information embodying concepts, ideas, techniques,
          proprietary information, know-how, formulations, market data, customer
          lists, product specifications and accounting data which is disclosed
          by one party hereto to the other.

                                       13
<PAGE>

     (b)  Non-Disclosure. During the period that this Agreement remains in
          effect and for a period of three (3) years following termination
          hereof, each party (except as is explicitly otherwise required hereby)
          shall keep confidential, shall not use for itself or for the benefit
          of others and shall not copy or allow to be copied in whole or in part
          any Confidential Information disclosed to such party by the other. The
          obligation of confidentiality imposed upon the parties by the
          foregoing paragraph shall not apply with respect to any alleged
          Confidential Information which:

          (1)  is known to the recipient thereof, as evidenced by said
               recipient's written records, prior to receipt thereof from the
               other party hereto;

          (2)  is disclosed to said recipient after the date hereof by the third
               party who has the right to make such disclosures and who does not
               violate any confidentiality agreement with the affected party
               hereto;

          (3)  is or becomes a part of the public domain through no fault of the
               said recipient; or

          (4)  is required by law or judicial or administrative process to be
               disclosed.

     (c)  IVAX DIAGNOSTICS and SIGMA shall agree to keep confidential and not
          disclose to third parties, the contents of this Agreement except as
          required by law or stock exchange rules, in which case the party
          required to disclose confidential information shall provide the other
          party with as much notice as is practicable.

     (d)  Each party agrees to limit access to Confidential Information to
          employees and agents having a need to know and to protect Confidential
          Information to the same extent as it protects its own trade secrets.

19.  Appointment of Sub-Distributors. SIGMA may assign, sublicense, delegate, or
     otherwise transfer the performance of the rights and obligations hereunder
     to qualified and reputable sub-distributors, provided, however, that: (i)
     SIGMA shall be liable to IVAX DIAGNOSTICS for the errors, negligent acts
     and omissions of its sub-distributor's as if such errors, negligent acts
     and omissions were its own, including any breach of any provision of this
     Agreement by the sub-distributors; (ii) SIGMA shall have and retain full
     control of any sub-distributors utilized, and shall be responsible for the
     performance by any sub-distributor; and (iii) SIGMA shall not be relieved
     of the responsibility for

                                       14
<PAGE>

     the proper performance and completion of the sub-distributed portions of
     its obligations hereunder.

20.  Successors. This agreement shall be binding upon the successors of IVAX
     DIAGNOSTICS and SIGMA, including successors who acquire the business assets
     of IVAX DIAGNOSTICS and SIGMA.

21.  Resolution of Disputes. In the event of any controversy or claim arising
     under or in relation to this agreement, including any issue about payment
     of amounts due, the parties shall, in good faith, attempt to resolve the
     controversy or claim by negotiation. If the controversy or claim cannot be
     resolved within sixty (60) days, then it shall be settled exclusively by
     arbitration in accordance with the Arbitration Rules of the American
     Arbitration Association (AAA) and shall be held in Atlanta, GA. There shall
     be three arbitrators: one selected by the party who requests arbitration
     who shall notify the other party of the person selected at the time that
     notice of arbitration is sent; one selected by the other party within ten
     (10) days of receipt of notice of arbitration and one selected by the
     parties jointly within ten (10) calendar days thereafter or, failing their
     agreement, selected pursuant to the rules of the AAA. No arbitrator shall
     be related to, employed by, or have at any time a substantial ongoing
     business relationship with any party hereto or any of their respective
     affiliates. The losing party in the arbitration shall reimburse the
     prevailing party for all costs and expenses, including reasonable attorney
     fees, incurred in connection with the arbitration. The decision of the
     arbitrators shall be final and binding on the parties and judgement upon
     the award rendered by the arbitrators may be entered by any court having
     jurisdiction thereof. The provisions of this arbitration clause shall not
     be applied to the determination of questions affecting validity or scope of
     any trademarks or other intellectual property rights.

22.  Notices. Any notice or other communication required or that shall be given
     pursuant to this Agreement shall be deemed sufficient if delivered
     personally, sent by facsimile, telegraph, or sent by certified, registered
     or express mail, postage prepaid to the address or facsimile number set
     forth below:

     To IVAX DIAGNOSTICS:                  WITH A COPY TO:
     IVAX DIAGNOSTICS, INC.                IVAX CORPORATION
     4400 Biscayne Blvd.                   4400 Biscayne Blvd.
     Miami, FL 33127                       Miami, FL 33137
     Facsimile No: (305) 324-2395          Facsimile No: (305)575-6049
     Attn: President                       Attn: General Counsel

                                       15
<PAGE>

     To SIGMA:
              Sigma Diagnostics
              545 South Ewing Avenue
              St. Louis, Missouri 63103
              Facsimile No: (314) 534-8461
              Attn: Vice President, Administration

     Either party may change the address to which notice to it is to be given,
     as provided herein.

23.  Entire Agreement. This Agreement and the exhibits referred to herein
     constitute the entire agreement between the parties and supersede all prior
     proposals, communications, representations and agreements, whether written
     or oral, with respect to the subject matter hereof. No change to the
     written terms of this Agreement shall be made except by written
     instrumentation executed by the parties hereto.

24.  No Waiver. The failure of either party to enforce at any time any of the
     provisions of this Agreement shall not be construed to be a waiver of those
     provisions or of the right of that party thereafter to enforce those
     provisions.

25.  Severability. If any provision of this Agreement is or becomes or is deemed
     invalid, illegal or unenforceable in any jurisdiction in which the
     Agreement is sought to be enforced, (a) such provision shall be deemed and
     amended to conform to applicable laws of such jurisdiction so as to be
     valid and enforceable or, if it cannot be so amended without materially
     altering the intention of the parties, it shall be stricken; (b) the
     validity, legality and enforceability of such provision will not in any way
     be affected or impaired thereby in any other jurisdiction; and (c) the
     remainder of this Agreement shall remain in full force and effect.

26.  Headings. The headings of this Agreement are included only for ease of
     reference and shall not affect the interpretation of this Agreement in any
     manner.

27.  Counterparts. This Agreement may be executed in any number of counterparts,
     each of which shall be deemed an original but all of which together shall
     constitute one and the same instrument.

28.  No Third Party Rights. The provisions of this Agreement are for the
     exclusive benefit of the parties to this Agreement, and no other party
     (including without limitation any creditor of any party to this Agreement)
     shall have any right or claim against any party to this Agreement by reason
     of those provisions or be entitled to enforce any of those provisions
     against any party to this Agreement.

                                       16
<PAGE>

29.  Relationship of Parties. This Agreement shall not constitute or be
     construed as creating a partnership or joint venture between SIGMA and IVAX
     DIAGNOSTICS, and neither party shall be liable for any debts or obligations
     of the other party.

30.  Limitation of Liability. Neither SIGMA nor IVAX DIAGNOSTICS nor any of
     their affiliates, employees, agents, officers or subcontractors shall have
     any liability for special, incidental, consequential or punitive damages or
     for economic loss as a result of any breach of this Agreement.

31.  Performance by Affiliates. SIGMA acknowledges and agrees that IVAX
     DIAGNOSTICS may perform certain of its obligations hereunder through its
     affiliates.

                                       17
<PAGE>

32.  THIS AGREEMENT CONTAINS A BINDING ARBITRATION PROVISION, WHICH MAY BE
     ENFORCED BY THE PARTIES.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duty authorized officers or authorized representatives

IVAX DIAGNOSTICS,INC.

By:/s/ Duane M. Steele
   ---------------------------------------
Title:Vice President-Business Developments
      ------------------------------------
Date: 10-12-00
     -------------------------------------

SIGMA DIAGNOSTICS, INC.

By:/s/
   ----------------------------
Title: V.P.Business Development
      --------------------------
Date: 10/9/00
      --------------------------

                                       18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]